Phase 3 Oral Insulin (ORMD-0801) Trials for the Treatment of Type 2 Diabetes: Over 75% Enrollment Completed
Upcoming Milestones: 6-month topline efficacy results from larger ORA-D-013-1 trial expected in 2022 ORA-D-013-2 trial expected to complete enrollment in 2022
Oravax Medical, Inc.: Oral COVID-19 Vaccine
Upcoming Milestones: Topline data from Phase 1 expected H1 2022 Initiation of Phase 2/3 oral COVID-19 vaccine trials expected H2 2022
Phase 2 NASH Trial: 50% Enrollment Completed
Upcoming Milestones: Enrollment completion expected H1 2022 Topline data expected in H2 2022
Oral GLP-1
Upcoming Milestone: Bioavailability (PK and PD) expected in H1 2022 https://www.oramed.com/oramed-issues-annual-message-to-shareholders/
|